GleamWall
中文EN

KYNB KYNTRA BIO, INC.

Pharmaceutical Preparations · Nasdaq · SEC CIK 921299 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY104.5%
TTM net income YoY-108.0%
TTM EPS YoY-108.0%
Revenue 3-yr CAGR-67.5%
Net income 3-yr CAGR—

Margins

Gross margin5.6%
Operating margin-1,089.4%
Net margin-326.0%
FCF margin-913.7%
EBITDA margin-1,089.4%

Returns

ROE—
ROA-18.6%
ROIC (approx.)—
Asset turnover0.06x

Leverage & solvency

Liabilities / assets114.7%
Debt / equity—
Current ratio1.16x
Interest coverage-6.53x

Cash quality & payout

Operating cash flow / net income2.80x
Accruals ratio33.5%
Payout ratio—
Capex / revenue0.0%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$6.44M$29.62M
Cost of revenue$556,000$15.56M
Gross profit$5.88M$14.06M
R&D expense$23.52M$95.69M
SG&A expense$27.71M$49.33M
Operating income-$45.90M-$150.42M
Interest expense$8.76M$8.25M
Pretax income-$58.29M-$153.37M
Income tax-$90,000-$269,000
Net income$183.45M-$47.58M
EBITDA-$45.18M-$147.76M
EPS (basic)45.37-11.89
EPS (diluted)45.37-11.89
Weighted avg. shares (diluted)4.04M4.00M
Balance sheet
Cash & equivalents$47.87M$50.48M
Short-term investments$41.11M$0
Receivables$216,000$481,000
Inventory$3.74M$3.15M
Current assets$99.07M$196.51M
PP&E, net—$0
Total assets$119.59M$214.53M
Current liabilities$29.24M$133.31M
Total liabilities$115.12M$398.16M
Shareholders' equity-$30.04M-$225.60M
Shares outstanding4.05M4.04M
Cash flow statement
Operating cash flow-$4.77M-$138.00M
Capital expenditure$38,000$266,000
Free cash flow-$4.81M-$138.26M
Investing cash flow$35.42M$125.99M
Financing cash flow-$86.03M-$255,000
Depreciation & amortization$713,000$2.65M
Stock-based compensation$6.58M$25.21M

Free plan shows the latest 2 periods; Pro shows all 13 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.